Ligand enters financing deal with AvenCell Therapeutics for up to $47 million

• Ligand Pharmaceuticals entered a financing agreement with AvenCell Therapeutics to fund next-generation allogeneic CAR-T programs for up to $47 million.
• Commitment includes up to $41 million for a mid single-digit to low double-digit royalty on worldwide net sales across AvenCell’s pipeline.
• Funding will be paid in four tranches, with later payments tied to clinical milestones and specified financing conditions.
• Ligand also committed up to $6 million in a concomitant Series C financing.
• Proceeds target development of AVC-201 in a Phase 1b AML expansion study, with AVC-203 in Phase 1a for B-cell malignancies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240700PRIMZONEFULLFEED9833027) on September 24, 2026, and is solely responsible for the information contained therein.